GO
Loading...

Patents

More

  • MUMBAI, April 10- India's Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.

  • CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.

  • Alkermes is a true drug innovator: CEO     Thursday, 10 Apr 2014 | 8:21 AM ET

    Richard Pops, chairman & CEO of Alkermes, discusses Alkermes' new injectable drug for the treatment of schizophrenia. We have more psychiatry products in our pipeline, reveals Pops.

  • Eli Lilly CEO: We keep investing in R&D     Thursday, 10 Apr 2014 | 6:51 AM ET

    John Lechleiter, Chairman, President & CEO of Eli Lilly, discusses the company's growth plans as products come off patent and consumers move to generic drugs.

  • Technology group Kudelski says Apple infringed patents Thursday, 10 Apr 2014 | 1:53 AM ET

    ZURICH, April 10- Technology group Kudelski said its OpenTV and Nagravision subsidiaries have filed a lawsuit against Apple Inc in a court in northern California alleging the iPhone maker has infringed five U.S. patents. Kudelski did not give further details about the patent suit. Apple was not immediately available for comment.

  • NXP in April 2012 sued BlackBerry, then known as Research in Motion, alleging that versions of the BlackBerry phone and PlayBook tablet infringed patents related to the design, data transmission and other features of those devices.

  • Apple, Intertrust settle year-old patent suit Friday, 4 Apr 2014 | 2:27 PM ET

    April 4- Apple Inc has agreed to settle a year-old patent infringement lawsuit with Intertrust Technologies Corp, a software firm owned by a group that includes Sony Corp and Philips, according to court filings. Intertrust filed a lawsuit against Apple in March 2013 saying the iPhone maker infringed 15 patents relating to security.

  • ZURICH, April 3- Novartis has taken India's Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday. In a hearing that took place on March 28, the Delhi court ordered that Biocon cannot manufacture, sell or export vildagliptin until the next court hearing, Novartis said in an emailed statement.

  • Samsung: Apple's claims are 'gross exaggeration' Tuesday, 1 Apr 2014 | 4:47 PM ET
    A man holds a Samsung Electronics Co. Galaxy S4 smartphone, left, next to an Apple Inc. iPhone 5.

    Samsung began its opening argument on Tuesday, saying that Apple's patents aren't nearly as broad or important as the company claims.

  • UPDATE 2-Marvell patent verdict grows to $1.54 billion Tuesday, 1 Apr 2014 | 11:15 AM ET

    April 1- A federal judge ordered Marvell Technology Group Ltd to pay nearly $1.54 billion to Carnegie Mellon University for selling billions of semiconductors that infringed the school's two hard disk drive patents.

  • O'Leary: Business is war; Apple strategy great     Tuesday, 1 Apr 2014 | 11:00 AM ET

    CNBC's Jon Fortt and investor Kevin O'Leary of "Shark Tank," discusses Apple's patent infringement battle with Samsung.

  • Apple and Samsung are back in court today for the latest chapter in their ongoing patent battle, reports CNBC's Josh Lipton.

  • SAN JOSE, Calif., April 1- Apple and Samsung return to federal court on Tuesday for opening statements in their latest patent battle, with the iPhone maker expected to present more detailed evidence in its attempt to win a U.S. ban on sales of several Samsung smartphones.

  • Marvell patent verdict grows to $1.54 billion Tuesday, 1 Apr 2014 | 12:32 AM ET

    April 1- A federal judge ordered Marvell Technology Group Ltd to pay nearly $1.54 billion for infringing two hard disk drive patents held by Carnegie Mellon University, nearly one-third more than a jury had previously awarded.

  • WASHINGTON, March 31- U.S. Supreme Court justices stepped gingerly into a raging debate over computer software on Monday, voicing concerns about vaguely defined patents but signaling they would avoid any radical change to existing law.

  • WASHINGTON, March 31- U.S. Supreme Court justices gave little indication on Monday they would set new guidelines on patent eligibility of software.

  • WASHINGTON, March 31- U.S. Supreme Court justices gave little indication on Monday they would set new guidelines on patent eligibility of software.

  • CNBC's Jon Fortt and Henry Blodget, Business Insider editor-in-chief & CEO, discuss the implications of a Supreme Court patent infringement case that could restrict the types of software and computer programs eligible for patent protection.

  • U.S. justices agree to hear Teva's Copaxone appeal Monday, 31 Mar 2014 | 9:36 AM ET

    By agreeing to hear the case, the high court cast into doubt a July 2013 ruling by the U.S. Court of Appeals for the Federal Circuit in favor of two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc and another involving Mylan Inc and Natco Pharma Ltd. The appeals court upheld some of nine patents involved in the drug, or portions thereof, but declared several invalid, meaning patent protections were set to expire in May 2014 instead of September 2015.

  • WASHINGTON, March 31- The U.S. Supreme Court will on Monday delve into the hotly contested question of when software is eligible for patent protection. Google Inc, Dell Inc, Verizon Communications Inc, Microsoft Corp, Hewlett-Packard Co and engine manufacturer Cummins Inc, are among the companies that have filed legal papers weighing in on the issue.